Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Receives $62.17 Average PT from Brokerages

Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) has earned an average recommendation of “Hold” from the seven research firms that are currently covering the company, MarketBeat Ratings reports. One analyst has rated the stock with a sell rating, two have given a hold rating and four have given a buy rating to the company. The average 12-month price target among brokers that have covered the stock in the last year is $62.1667.

A number of analysts have commented on SUPN shares. Zacks Research upgraded shares of Supernus Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research report on Monday, April 27th. Weiss Ratings reiterated a “sell (d+)” rating on shares of Supernus Pharmaceuticals in a report on Friday, March 27th. Craig Hallum set a $65.00 target price on shares of Supernus Pharmaceuticals in a report on Wednesday, February 25th. Finally, Wall Street Zen downgraded shares of Supernus Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Saturday.

Supernus Pharmaceuticals Stock Down 2.4%

Shares of NASDAQ:SUPN opened at $48.21 on Friday. The company has a market cap of $2.80 billion, a PE ratio of -94.53, a P/E/G ratio of 1.06 and a beta of 0.57. The company’s 50-day moving average price is $49.99 and its 200 day moving average price is $49.68. Supernus Pharmaceuticals has a fifty-two week low of $30.83 and a fifty-two week high of $59.68.

Insider Buying and Selling at Supernus Pharmaceuticals

In other news, Director Georges Gemayel sold 8,787 shares of the business’s stock in a transaction that occurred on Friday, March 6th. The shares were sold at an average price of $53.00, for a total transaction of $465,711.00. Following the sale, the director owned 27,277 shares in the company, valued at $1,445,681. The trade was a 24.37% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Jack A. Khattar sold 35,000 shares of the business’s stock in a transaction that occurred on Friday, March 13th. The shares were sold at an average price of $50.37, for a total transaction of $1,762,950.00. Following the sale, the chief executive officer owned 958,100 shares in the company, valued at $48,259,497. This represents a 3.52% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 116,406 shares of company stock valued at $5,911,086 over the last quarter. Company insiders own 8.80% of the company’s stock.

Institutional Investors Weigh In On Supernus Pharmaceuticals

A number of large investors have recently made changes to their positions in the company. Jefferies Financial Group Inc. grew its position in Supernus Pharmaceuticals by 62.0% during the third quarter. Jefferies Financial Group Inc. now owns 86,179 shares of the specialty pharmaceutical company’s stock valued at $4,118,000 after purchasing an additional 32,979 shares in the last quarter. Tudor Investment Corp ET AL purchased a new position in Supernus Pharmaceuticals during the third quarter valued at approximately $1,434,000. Phocas Financial Corp. purchased a new position in Supernus Pharmaceuticals during the fourth quarter valued at approximately $4,042,000. Ruffer LLP purchased a new position in Supernus Pharmaceuticals during the third quarter valued at approximately $2,647,000. Finally, Teacher Retirement System of Texas grew its position in Supernus Pharmaceuticals by 648.9% during the third quarter. Teacher Retirement System of Texas now owns 112,638 shares of the specialty pharmaceutical company’s stock valued at $5,383,000 after purchasing an additional 97,597 shares in the last quarter.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc, headquartered in Rockville, Maryland, is a specialty pharmaceutical company dedicated to developing and commercializing central nervous system (CNS) therapies. Since its founding in 2003, Supernus has focused on advancing treatments for neurological disorders, with an emphasis on improving patient quality of life through innovative dosage forms and sustained‐release formulations.

The company’s marketed portfolio includes Trokendi XR and Oxtellar XR, extended‐release antiepileptic medications designed to maintain stable drug levels for seizure control, as well as Qelbree (viloxazine extended‐release capsules), approved for the treatment of attention‐deficit/hyperactivity disorder (ADHD) in pediatric and adult patients.